Abstract 969P
Background
Alpha-fetoprotein (AFP) is widely used for HCC screening in at-risk populations, but its performance is suboptimal. Routine blood test panels provide insights on multiple cancer-related conditions and have shown to improve detection in other cancers. Hence, we explore the foundation for a new high-dimensional data approach taking multiple routine laboratory parameters and their intricate interactions into consideration with AI. In this study, a routine blood test signature for HCC derived from big clinical data is described
Methods
This is a population-based retrospective study. Patient records from 2000 to 2018 were retrieved from the Hong Kong Hospital Authority Data Collaboration Laboratory. CLD patients with and without HCC were identified based on ICD codes, antiviral drug history, virology test and radiology reports. Patients with decompensated CLD were excluded. Routine blood tests retrieved included CBC, LFT, RFT and clotting profile. Blood records within one month before the diagnosis of HCC and CLD patients were retrieved. Statistical analysis included descriptive statistics and Mann-Whitney U (MWU) test.
Results
The cohort yielded 223,862 patients including 31,149 patients with HCC (13.9%) and 192,713 without. Statistical test results showed a distinctive spectral signature for HCC patients compared to those without HCC. It is characterized by the concurrent presence of more significant liver function derangement (raised ALT, ALP, bilirubin, AST and decreased albumin), tendency for systemic inflammation (lower lymphocyte and RDW), tendency for bleeding (prolonged PT and APTT, low platelet) and suggestions of cachexia (lower albumin, creatinine and urea), all were statistically significant (P<0.05, MWU test)
Conclusions
This is the first study to describe a routine blood signature for HCC detection established by big clinical data. The spectral characteristics of HCC separated well from CLD controls. The novel spectrum provides solid clinical ground for the use of advanced machine learning to generate an interactive classification model to detect HCC. In a companion abstract, we describe the development of the proposed signature, which is shown to be superior to AFP in HCC screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hong Kong University of Science and Technology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18